KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination With PI3K Inhibition.

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0368
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Direct Inhibition of Oncogenic KRAS by Hydrocarbon-Stapled SOS1 Helices

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2015English

BET Inhibition Is an Effective Approach Against KRAS-driven PDAC and NSCLC

Oncotarget
Oncology
2018English

Allele-Specific Inhibitors Inactivate Mutant KRAS G12C by a Trapping Mechanism

Science
MultidisciplinaryPhilosophy of ScienceHistory
2016English

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2014English

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models

Clinical Cancer Research
Cancer ResearchOncology
2011English

SREBP1 Regulates Mitochondrial Metabolism in Oncogenic KRAS Expressing NSCLC

2020English

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS -Mutant Lung Cancer

Cancer Discovery
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy